High Dose of Erythropoietin Analogue After Cardiac Arrest
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesised that the neuroprotective effects of erythropoietin and its
analogues could lead to an improve outcome after cardiac arrest. To test this hypotheses, the
investigators designed a randomized, multicentre, simple blind trial in which all
participating patients will be receive usual treatments and 50% of them will also receive a
high dose of epoetin alpha (an analogue of erythropoietin) in an "add on" fashion. The main
end point will be the proportion of patients in each arm who will reach at day 60 the best
level of recovery, using a 5 level score.